Idexx Laboratories (IDXX) Cash from Financing Activities (2009 - 2026)

Idexx Laboratories has reported Cash from Financing Activities for 18 years, with the latest figure at -$325.2 million in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 96.33% year-over-year to -$325.2 million in Q2 2026; TTM through Jun 2026 was -$1.2 billion, a 18.23% decrease from a year earlier, with the FY2025 full-year figure at -$1.2 billion, down 32.67% from the prior year.
• Cash from Financing Activities was -$325.2 million for Q2 2026 at Idexx Laboratories, down from -$211.4 million in the prior quarter.
• The five-year high for Cash from Financing Activities was -$13.5 million in Q1 2022, with the low at -$355.7 million in Q4 2025.
• Average Cash from Financing Activities over 5 years is -$188.5 million, with a median of -$158.3 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities jumped 89.6% in 2022, then plunged 983.69% in 2023.
• Over 5 years, Cash from Financing Activities stood at -$116.7 million in 2022, then gained by 12.75% to -$101.8 million in 2023, then slumped by 128.57% to -$232.8 million in 2024, then tumbled by 52.8% to -$355.7 million in 2025, then grew by 8.58% to -$325.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$325.2 million (Q2 2026), -$211.4 million (Q1 2026), and -$355.7 million (Q4 2025), per Business Quant data.